• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD. Expand
Parkinson’s disease: clinical features and diagnosis
  • J. Jankovic
  • Medicine
  • Journal of Neurology, Neurosurgery, and…
  • 14 March 2008
A thorough understanding of the broad spectrum of clinical manifestations of PD is essential to the proper diagnosis of the disease and genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk. Expand
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
Criteria that support the diagnosis of progressive supranuclear palsy, and that exclude diseases often confused with PSP, are presented. Expand
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications. Expand
Phenomenology and classification of dystonia: A consensus update
An international panel consisting of investigators with years of experience in this field that reviewed the definition and classification of dystonia provides a new general definition and proposes a new classification and encourages clinicians and researchers to use these innovative definitions and test them in the clinical setting on a variety of patients with Dystonia. Expand
The Parkinson Progression Marker Initiative (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding ofExpand
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
It is demonstrated that total DJ-1 and alpha-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration. Expand
Variable expression of Parkinson's disease
Among the patients participating in the DATATOP, older age at onset with bradykinesia, or with the PIGD form of PD, is associated with more functional disability than when the symptoms are dominated by tremor or begin at a younger age. Expand
Paroxysmal dyskinesias: Clinical features and classification
A new classification, based chiefly on precipitating events, allowed appropriate categorization of the attacks in all patients with paroxysmal dyskinesias. Expand
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001). Expand